Thyroid papillary carcinoma after alemtuzumab therapy for MS
- 1 August 2014
- journal article
- Published by Springer Nature in Journal of Neurology
- Vol. 261 (9) , 1828-1829
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Low risk papillary thyroid cancerBMJ, 2014
- The Increasing Incidence of Thyroid Cancer: The Influence of Access to CareThyroid®, 2013
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialThe Lancet, 2012
- Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005Cancer Epidemiology, Biomarkers & Prevention, 2009